Mundipharma has licensed exclusive global ex-US rights to Zubsolv. Deal terms include a €7m upfront payment, in addition to further undisclosed regulatory and commercial milestones and up to low double-digit net sales royalties. Ahead of Orexo’s Q216 results on 12 July pending further disclosures, we make no changes to our current forecast and valuation. Nevertheless, this is an important deal for Orexo, which will significantly expand the Zubsolv market opportunity ex-US, where c 20 million people are estimated to be afflicted by opioid dependence. Access to the global opioid dependence market is a key growth driver for Orexo, in addition to the anticipated expansion in US prescribing rights and the currently undisclosed development pipeline.
